Event Internal Blog Post Sample Copy – Internal Communication 2014

Allicense 2014 - April 29-30 - Event Details

Blog Post created by Jillian Tygh on Apr 2, 2014

- <u>Like</u> Show 1 Like<u>1</u>
 - <u>Comment</u> 0

ALLICENSE 2014: THE NEXT GENERATION OF DEALMAKING

With the acquisition of Recap comes the acquisition of the annual dealmaking conference, <u>Allicense</u>. Thomson Reuters will be hosting this event in San Francisco, April 29th-30th, with the support of our sponsored co-hosts: Locust Walk Partners, the ABD Team, Silicon Valley Bank, BayBio, Russel Reynolds, Alexandria Real Estate Equities, and Fenwick & West, LLP.

Recap has hosted this event for the past 18 years with significant success. This year, it returns with a twist, focusing on the next generation of biopharma dealmakers, covering a host of controversial topics such as "Are Big Pharma companies taking a back seat in M&A dealmaking?" and "Is Venture Capital dead?".

EVENT DETAILS

Date: April 29 - 30, 2014

Location: The Palace Hotel | 2 New Montgomery Street | San Francisco, CA

Website: www.allicense.com

SFDC Link:https://na5.salesforce.com/70170000000UmV5?srPos=2&srKp=701

Major Event Themes: Next Generation of Dealmaking, Biopharma deals, Impact of Healthcare

Reform on Biopharma, Industry Controversy

KEYNOTE SPEAKERS

Zeke Emanuel, Joint Appointment - Wharton School & School of Medicine, University of Pennsylvania

Ari Fleischer, Former White House Press Secretary for U.S. President George W. Bush 2001-2003

Kenneth Moch, CEO, Chimerix

Paul Hastings, CEO, Oncomed

Robin Smith, CEO, NeoStem

Tracey Mumford, Senior Director, Michael J. Fox Foundation

For a full list of speakers please visit our website: www.allicense.com

PRESS ATTENDING

Adam Feuerstein, Sr. Columnist, TheStreet **Luke Timmerman**, Columnist, Xconomy

Ron Leuty, Biotech Reporter, San Francisco Business Times

Marie Daghlian, Director of Communications, The Burrill Report

Peter Winter, Editor, BioWorld

TARGET AUDIENCE

- Pharma/Biotech C-level Contacts
- BD&L Executives, Corporate Development Executives
- VCs and Investment Bankers

HOW YOU CAN HELP

- You can forward the attached emails to your personal contacts
- Share Allicense tweets from <a>@Cortellis on your twitter feeds or you can start by retweeting the social selling posts below:

The Dealmaking landscape has shifted. Are you ready for the Next Generation of Dealmaking? Learn more @ Allicense2014 http://bit.ly/liLnaW4

@pfizer@LillyPadhttp://bit.ly/1jHnd2H #Allicense2014

Zeke Emanuel and Ari Fleischer discuss the impact of healthcare reform on biopharma. Join them at Allicense 2014 http://bit.ly/liLnaW4

OncoMed and @Celgenehttp://bit.ly/1jHnd2H_#Allicense2014

Aragon Pharma + J&J @JNJNewshttp://bit.ly/1jHnd2H #Allicense2014

Meet the new players and learn about current trends in biopharma dealmaking at Allicense2014 this April http://bit.ly/liLnaW4

Voting is now open to select the most innovative M&A / licensing deal of 2013. Who should win? http://bit.ly/1jHnd2H #Allicense2014

Who makes a better licensing partner? Established pharma or emerging specialty biopharma players? http://bit.ly/liLnaW4 #Allicense2014

Moderna Therapeutics and <u>@AstraZenecahttp://bit.ly/1jHnd2H</u> #Allicense2014

Okairos and <u>@GSKhttp://bit.ly/1jHnd2H</u> #Allicense2014

• Reference <u>#Allicense2014</u> on any/all tweets

- Share posts regarding Allicense on Linkedin & Twitter
- Include the below in your email signature:

JOIN US: ALLICENSE 2014 - THE NEXT GENERATION OF DEALMAKING APRIL 29-30 | THE PALACE HOTEL | SAN FRANCISCO WWW.ALLICENSE.COM

If you have any questions, please feel free to reach out to either Jillian Tygh or Karla Burke.

ATTACHMENTS

- Join the next generation of dealmakers (5).html.zip3.4 KB
- Allicense 2014 Who Would You Prefer to Partner with the Established or the Aggressors .html.zip 3.7 KB
- Allicense 2014 Is Big Pharma on the Way Out .html.zip3.5 KB
- Allicense 2014 Wheres Your Money in the Life Sciences Funding Divide .html.zip3.5 KB